Finance

Lists
Why is 326030 up 3,96%?
Dive Deeper
326030:KRX
SK Biopharmaceuticals Co Ltd
76 200,00 KRW
+3,96%
(+2 900,00) 1D
19-окт., 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 326030...
Open
73 100 KRW
High
76 400 KRW
Low
72 400 KRW
Mkt. cap
5,97 трлн
Avg. vol.
109,14 миң
Volume
90,11 миң
P/E ratio
14,88
52-wk high
144 100 KRW
52-wk low
67 800 KRW
EPS
5 120 KRW
Shares outstanding
78,31 млн
No. of employees
246
Open
73 100 KRW
High
76 400 KRW
Low
72 400 KRW
Mkt. cap
5,97 трлн
Avg. vol.
109,14 миң
Volume
90,11 миң
P/E ratio
14,88
52-wk high
144 100 KRW
52-wk low
67 800 KRW
EPS
5 120 KRW
Shares outstanding
78,31 млн
No. of employees
246
News stories
From web sources and news partners
About SK Biopharmaceuticals Co Ltd
CEO-
Employees246
Founded1993
Headquarters-
SectorPharmaceutical industry
Websiteskbp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
191,73 млд
194,36 млд
227,89 млд
247,37 млд
Cost of goods sold
7,55 млд
14,95 млд
14,33 млд
15,02 млд
Cost of revenue
7,55 млд
14,95 млд
14,33 млд
15,02 млд
Research and development expenses
40,93 млд
51,85 млд
47,59 млд
49,66 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
68,98 млд
77,42 млд
71,09 млд
81,28 млд
Operating expense
114,07 млд
133,13 млд
123,79 млд
135,29 млд
Total operating expenses
121,62 млд
148,08 млд
138,12 млд
150,30 млд
Operating income
70,11 млд
46,28 млд
89,77 млд
97,06 млд
Other non operating income
-8,46 млд
-7,51 млд
-5,78 млд
-5,76 млд
EBT including unusual items
62,11 млд
33,76 млд
99,98 млд
93,36 млд
EBT excluding unusual items
61,27 млд
36,66 млд
89,89 млд
89,81 млд
Income tax expense
-9,26 млд
-98,98 млд
-2,76 млд
8,30 млд
Effective tax rate
-14,90%
-293,19%
-2,76%
8,88%
Other operating expenses
1,37 млд
1,11 млд
2,22 млд
1,42 млд
Net income
74,14 млд
136,59 млд
105,16 млд
85,06 млд
Net profit margin
38,67%
70,28%
46,15%
34,39%
Earnings per share
-
-
-
-
Interest and investment income
1,88 млд
1,72 млд
1,68 млд
2,37 млд
Interest expense
-1,70 млд
-1,32 млд
-1,30 млд
-1,26 млд
Net interest expenses
179,24 млн
397,10 млн
380,91 млн
1,11 млд
Depreciation and amortization charges
2,23 млд
2,18 млд
2,19 млд
2,17 млд
EBITDA
74,11 млд
50,23 млд
93,70 млд
101,08 млд
Gain or loss from assets sale
10,55 млн
176,00 млн
-
1,00 миң
AI content may include mistakes. Learn more
Google колдонмолору